These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 34303849)
21. Immunopathogenesis and immunobiology of SARS-CoV-2. Rabaan AA; Al-Ahmed SH; Al Mutair A; Alhumaid S; Sule AA; Tirupathi R; Fawzy M; Muhammad J; Khan A; Hasan A; Shrestha DB; Sah R; Dhawan M; Tiwari R; Bilal M; Ahmad T; Dhama K Infez Med; 2021 Jun; 29(2):167-180. PubMed ID: 34061781 [TBL] [Abstract][Full Text] [Related]
22. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Varghese PM; Tsolaki AG; Yasmin H; Shastri A; Ferluga J; Vatish M; Madan T; Kishore U Immunobiology; 2020 Nov; 225(6):152008. PubMed ID: 33130519 [TBL] [Abstract][Full Text] [Related]
23. Pattern Recognition Proteins: First Line of Defense Against Coronaviruses. Labarrere CA; Kassab GS Front Immunol; 2021; 12():652252. PubMed ID: 34630377 [TBL] [Abstract][Full Text] [Related]
24. A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. Sánchez-Zuno GA; Matuz-Flores MG; González-Estevez G; Nicoletti F; Turrubiates-Hernández FJ; Mangano K; Muñoz-Valle JF Int J Immunopathol Pharmacol; 2021; 35():20587384211050199. PubMed ID: 34632844 [TBL] [Abstract][Full Text] [Related]
25. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287 [TBL] [Abstract][Full Text] [Related]
26. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
27. COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants. Cevik M; Grubaugh ND; Iwasaki A; Openshaw P Cell; 2021 Sep; 184(20):5077-5081. PubMed ID: 34534444 [TBL] [Abstract][Full Text] [Related]
28. A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. Minakshi R; Jan AT; Rahman S; Kim J Front Cell Infect Microbiol; 2020; 10():575404. PubMed ID: 33262955 [TBL] [Abstract][Full Text] [Related]
29. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects. Zheng J; Deng Y; Zhao Z; Mao B; Lu M; Lin Y; Huang A Cell Mol Immunol; 2022 Feb; 19(2):150-157. PubMed ID: 34645940 [TBL] [Abstract][Full Text] [Related]
30. Omicron: Call for updated vaccines. Li X J Med Virol; 2022 Apr; 94(4):1261-1263. PubMed ID: 34927258 [TBL] [Abstract][Full Text] [Related]
31. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. Volkan E Mol Biotechnol; 2021 Oct; 63(10):885-897. PubMed ID: 34145550 [TBL] [Abstract][Full Text] [Related]
32. Revelation of Potent Epitopes Present in Unannotated ORF Antigens of SARS-CoV-2 for Epitope-Based Polyvalent Vaccine Design Using Immunoinformatics Approach. Uttamrao PP; Sathyaseelan C; Patro LPP; Rathinavelan T Front Immunol; 2021; 12():692937. PubMed ID: 34497604 [TBL] [Abstract][Full Text] [Related]
33. T Cells: Warriors of SARS-CoV-2 Infection. de Candia P; Prattichizzo F; Garavelli S; Matarese G Trends Immunol; 2021 Jan; 42(1):18-30. PubMed ID: 33277181 [TBL] [Abstract][Full Text] [Related]
34. Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative. Kyei-Barffour I; Addo SA; Aninagyei E; Ghartey-Kwansah G; Acheampong DO Biomed Pharmacother; 2021 Dec; 144():112282. PubMed ID: 34624675 [TBL] [Abstract][Full Text] [Related]
36. Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. Borges RC; Hohmann MS; Borghi SM Int Rev Immunol; 2021; 40(1-2):108-125. PubMed ID: 33191813 [TBL] [Abstract][Full Text] [Related]
37. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923 [TBL] [Abstract][Full Text] [Related]
38. Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics. Ebrahimi N; Aslani S; Babaie F; Hemmatzadeh M; Hosseinzadeh R; Joneidi Z; Mehdizadeh Tourzani Z; Pakravan N; Mohammadi H Int Immunopharmacol; 2020 Dec; 89(Pt B):107082. PubMed ID: 33068865 [TBL] [Abstract][Full Text] [Related]
39. An Update on Innate Immune Responses during SARS-CoV-2 Infection. Zhang Y; Chen S; Jin Y; Ji W; Zhang W; Duan G Viruses; 2021 Oct; 13(10):. PubMed ID: 34696490 [TBL] [Abstract][Full Text] [Related]
40. Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms. Bayat M; Asemani Y; Najafi S Int Immunopharmacol; 2021 Aug; 97():107679. PubMed ID: 33930707 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]